PCH
RAPP

Polar Capital Holdings’s Rapport Therapeutics RAPP Stock Holding History

Polar Capital Holdings’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67M Sell
1,608,514
-33,947
-2% -$1.25M 0.16% 105
2026
Q1 		$51.4M Buy
1,642,461
+637,733
+63% +$17.9M 0.18% 93
2025
Q4 		$30.5M Buy
1,004,728
+65,776
+7% +$1.82M 0.12% 128
2025
Q3 		$27.9M Buy
+938,952
New +$16.7M 0.13% 126

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Polar Capital Holdings's RAPP Position: Q2 2026 in Review

Polar Capital Holdings reduced its Rapport Therapeutics (RAPP) stake by 2.1% in Q2 2026, selling an estimated $1.25M and leaving 1,608,514 shares worth $67M. The position accounts for 0.16% of the portfolio, ranked #105.

Polar Capital Holdings first reported a position in RAPP in Q3 2025 and has held it in 4 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Polar Capital Holdings held 1,608,514 shares of Rapport Therapeutics worth $67M as of Q2 2026.
  • Polar Capital Holdings sold 33,947 Rapport Therapeutics shares in Q2 2026, an estimated $1.25M.
  • Rapport Therapeutics made up 0.16% of Polar Capital Holdings's portfolio in Q2 2026, its #105 holding.
  • Polar Capital Holdings first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.